- Home
- NTRB vs RLYB Comparison
NTRB vs RLYB Comparison
Compare NTRB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | RLYB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 24.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTRB | RLYB |
|---|---|---|
| Price | $5.42 | $0.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 185.6K |
| Earning Date | 12-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | $674,000.00 |
| Revenue This Year | $30.17 | $17.61 |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.69 | ★ 12.71 |
| 52 Week Low | $3.72 | $0.22 |
| 52 Week High | $11.78 | $1.08 |
Technical Indicators
Market Signals| Indicator | NTRB | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 48.07 |
| Support Level | $4.34 | $0.64 |
| Resistance Level | $4.77 | $0.80 |
| Average True Range (ATR) | 0.45 | 0.06 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 57.25 | 34.13 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.